• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    1,178.93 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 13
    Open 1,178.93
    Bid (Size) 1,139.80 (1)
    Ask (Size) 1,194.00 (1)
    Prev. Close 1,178.93
    Today's Range 1,178.93 - 1,178.93
    52wk Range 769.19 - 1,211.20
    Shares Outstanding 91,779,465
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Biotech And Life Science Sector Update Summer Of 2024
    It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
    Via Talk Markets
    Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
    Via Benzinga

    Performance

    YTD
    +30.27%
    +30.27%
    1 Month
    +9.38%
    +9.38%
    3 Month
    +21.55%
    +21.55%
    6 Month
    +22.03%
    +22.03%
    1 Year
    +41.20%
    +41.20%

    More News

    Read More
    Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    What Analysts Are Saying About Regeneron Pharmaceuticals Stock
    Via Benzinga
    If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
    Via Benzinga
    Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
    Via Benzinga
    10 Bagger Stocks: Can You Find One?
    Via Talk Markets
    Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
    Via Benzinga
    Exposures Product Safety
    Regeneron Provides Update on Biologics License Application for Linvoseltamab
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Biotech Bull Market: 3 Ways To Play It
    Via Talk Markets
    Topics Economy
    Exposures Interest Rates
    $100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
    Via Benzinga
    Analyst Ratings For Regeneron Pharmaceuticals
    Via Benzinga
    Alphabet Turns Twenty
    Via Talk Markets
    7 Stocks That Usually Benefit From a Recession
    Via InvestorPlace
    3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
    Via InvestorPlace
    3 Biotech Stocks With Promising Drug Pipelines: August 2024
    Via InvestorPlace
    Exposures Product Safety
    Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    3 Healthcare Stocks Positioned for Possible Market Outperformance
    Via InvestorPlace
    Is Regeneron Pharmaceuticals Due for a Stock Split?
    Via The Motley Fool
    Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
    Via Investor's Business Daily
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
    Via Benzinga
    US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
    Via Benzinga
    Regeneron Stock Climbs After Strong Second-Quarter Performance
    Via Investor's Business Daily
    Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.